Perspective Therapeutics, Inc. (CATX) Stock Score, Valuation & Financial Research

Perspective Therapeutics, Inc. is in the Healthcare sector and Medical - Devices industry. It is reviewed using Wall Street Score's company-strength, valuation, growth and financial-health framework. A complete Wall Street Score is not currently available.

Quick answer for CATX

Perspective Therapeutics, Inc. does not currently have a complete Wall Street Score. The stored market price is USD 2.75. These figures are a research snapshot, not a buy or sell recommendation.

What Perspective Therapeutics, Inc. does

Perspective Therapeutics, Inc., including its various operations, specializes in the comprehensive lifecycle – from development and manufacturing to sales and marketing – of radiopharmaceutical products and medical devices. These advanced solutions are designed to treat cancer and other serious malignant conditions, serving markets both within the United States and globally. A flagship product offered by the company is its CS-1 Cesium-131 brachytherapy seeds. This treatment is specifically utilized for a broad range of cancers, such as those impacting the prostate, brain, lung, head and neck regions, gynecological system, pelvic/abdominal areas, and colorectal tissues. The company distributes its products to medical facilities and physician practices equipped with surgical capabilities. The entity originally operated under the name Isoray, Inc., before officially adopting the name Perspective Therapeutics, Inc. in February 2022. Founded in 1998, the company maintains its corporate headquarters in Richland, Washington.

Company business and revenue

Research reporting period: 2025-12-31. A research update is not a new financial filing.

How the company makes money

Perspective Therapeutics is a radiopharmaceutical company that generates revenue primarily through the sale of medical devices, specifically Cesium-131 brachytherapy seeds used in cancer treatment. The company is also actively developing a pipeline of targeted alpha-particle therapies (TATs) and currently funds its operations through capital raises and research collaborations while transitioning toward a clinical-stage biotechnology business model.

Products and services

  • The company manufactures and sells Cesium-131 brachytherapy seeds for the treatment of various cancers and is developing a portfolio of targeted alpha-particle therapies (TATs) using isotopes like Lead-212.

Brands and product families

  • Cesium-131 — Brachytherapy seed product line. Source

Customer types

Hospitals; Cancer treatment centers.

Suppliers, materials and equipment

  • Isotope suppliers — The company relies on third-party suppliers for the procurement of radioactive isotopes used in its brachytherapy products and clinical development programs. Source

Business relationships and partnerships

  • Bristol Myers Squibb — Clinical trial collaboration agreement to evaluate the safety and tolerability of [212Pb] VMT01 in combination with nivolumab in patients with melanoma. Source
  • Merck — Clinical collaboration and supply agreement to evaluate [212Pb] VMT-α-NET in combination with pembrolizumab in patients with solid tumors. Source

Competitors and product-market comparisons

  • Radiopharmaceutical developers — Various biotechnology and pharmaceutical companies developing targeted alpha-particle therapies and other radiopharmaceuticals. Source

Business strengths to evaluate

  • Proprietary Lead-212 platform technology Source
  • Established commercial infrastructure for brachytherapy Source

Business risks and research considerations

  • History of operating losses and need for additional capital Source
  • Dependence on clinical trial success and regulatory approvals Source

Sources: Company research source · Merck

Company research refreshed 2026-10-12. This is saved research, not a live check of company relationships. Check the reporting period and source disclosures. Financial figures and scores follow their separate update schedules.

CATX financial snapshot

Statement amounts: USD. Quote amounts: USD. No exchange-rate conversion is performed in this snapshot. Market-capitalization currency is not supplied by this projection.

Wall Street Score:
Not currently available
Stored price:
USD 2.75
Market capitalization:
313.63M (currency not supplied)
Revenue:
USD 366K
Net income:
USD -116.43M
Free cash flow:
USD -95.23M
Cash:
USD 48.49M
Total debt:
USD 3.96M
EPS:
USD -1.56

What stands out

  • Free cash flow is USD -95.23M, negative for the stored period.
  • The balance sheet shows USD 48.49M of cash versus USD 3.96M of total debt, an excess of cash over debt on these two reported measures.
  • The current research record carries a fundamental change risk warning, which should be reviewed alongside the score.

Company-specific financial comparisons

The following are calculated from saved company data, not forecasts or statements about future performance. Differences in reporting dates or units can make a ratio misleading; verify the original filings.

  • Cash exceeds debt by USD 44.53M using the stored balance-sheet values. This does not include other obligations or restricted cash.

Questions worth answering for CATX

Use these questions to check the stored figures against the latest company filings. They identify issues to investigate; they are not findings about management's plans or future results.

  • How long can CATX fund negative free cash flow using its current cash position before it may need more debt or new shares?
  • How is CATX likely to use its cash advantage: reinvestment, acquisitions, debt reduction, dividends or buybacks?
  • What specifically needs to improve for CATX to reach sustainable profitability?
  • What does the current fundamental change risk warning mean for the reliability or interpretation of CATX's score?

What the numbers mean

A complete valuation score is not currently available, so valuation should be checked using the available earnings, cash-flow and price data.

A complete financial score is not currently available, so investors should review cash, debt, earnings and cash flow directly.

A strong company and an attractive stock price are not always the same thing. Revenue, earnings, free cash flow, debt, management quality, competitive advantage and valuation should be considered together. Wall Street Score organizes these inputs into a consistent research framework so investors can identify what deserves deeper review.

Data freshness: Financial data last refreshed 2026-10-01.

Research-input completeness: 73% of the scoring inputs required for this public page are currently available.

How to research CATX

Start by understanding how the company makes money. Then compare revenue and earnings trends, cash generation, debt, liquidity and valuation. Review the company's latest filings and earnings reports before acting on any score or model estimate.

Learn how to analyze a stock · Read the Wall Street Score methodology · Browse other stocks

Data may change as company filings and market prices update. Educational research only; not a buy or sell recommendation.